Journal of Genetic Counseling

, Volume 20, Issue 1, pp 5–19

Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review

  • Scott M. Weissman
  • Cecelia Bellcross
  • Christina Chimera Bittner
  • Mary E. Freivogel
  • Joy Larsen Haidle
  • Pardeep Kaurah
  • Anna Leininger
  • Selvi Palaniappan
  • Kelle Steenblock
  • Thuy M. Vu
  • Molly S. Daniels
Professional Issues

Abstract

Lynch syndrome is the most common hereditary colorectal cancer syndrome and the most common cause of hereditary endometrial cancer. Identifying and evaluating families for Lynch syndrome is increasing in complexity due to the recognition that: family history-based clinical criteria lack sensitivity and specificity; genetic testing for Lynch syndrome continues to evolve as understanding of the molecular mechanisms underlying it evolves; and the Lynch syndrome phenotype encompasses multiple organ systems and demonstrates overlap with other hereditary cancer syndromes. This document is a summary of considerations when evaluating individuals and families for Lynch syndrome, including information on cancer risks, diagnostic criteria, tumor and genetic testing strategies, and the management of individuals with this condition.

Keywords

Genetic testing Hereditary colorectal cancer Hereditary nonpolyposis colorectal cancer HNPCC Immunohistochemistry Lynch syndrome Microsatellite instability Risk assessment Tumor studies 

References

  1. Aaltonen, L. A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomaki, P., et al. (1998). Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. The New England Journal of Medicine, 338(21), 1481–1487.PubMedGoogle Scholar
  2. Aarnio, M., Salovaara, R., Aaltonen, L. A., Mecklin, J. P., & Jarvinen, H. J. (1997). Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. International Journal of Cancer, 74, 551–555.Google Scholar
  3. Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., et al. (1999). Cancer risk in mutation carriers of DNA-mismatch-repair genes. International Journal of Cancer, 81(2), 214–218.Google Scholar
  4. Abbas, O., & Mahalingam, M. (2009). Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. Journal of Cutaneous Pathology, 36(6), 613–619.PubMedGoogle Scholar
  5. Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., et al. (2009). Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 114(3), 486–490.PubMedGoogle Scholar
  6. Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2009). Risks of Lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201.PubMedGoogle Scholar
  7. Balmana, J., Stockwell, D. H., Steyerberg, E. W., Stoffel, E. M., Deffenbaugh, A. M., Reid, J. E., et al. (2006). Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA, 296(12), 1469–1478.PubMedGoogle Scholar
  8. Bandipalliam, P. (2005). Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer, 4(4), 323–333.PubMedGoogle Scholar
  9. Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763.PubMedGoogle Scholar
  10. Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242.PubMedGoogle Scholar
  11. Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141–149.PubMedGoogle Scholar
  12. Berends, M. J., Hollema, H., Wu, Y., van Der Sluis, T., Mensink, R. G., ten Hoor, K. A., et al. (2001). MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. International Journal of Cancer, 92(3), 398–403.Google Scholar
  13. Berends, M. J., Wu, Y., Sijmons, R. H., Mensink, R. G., van der Sluis, T., Hordijk-Hos, J. M., et al. (2002). Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. American Journal of Human Genetics, 70(1), 26–37.PubMedGoogle Scholar
  14. Boland, C. R. (2005). Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer, 4(3), 211–218.PubMedGoogle Scholar
  15. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research, 58(22), 5248–5257.PubMedGoogle Scholar
  16. Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Moslein, G., Olschwang, S., et al. (2008). Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. The New England Journal of Medicine, 359(24), 2567–2578.PubMedGoogle Scholar
  17. Burn, J., Gerdes, A. M., Mecklin, J. P., Macrae, F., Moeslein, G., Olschwang, S., et al. (2009). Aspirin prevents cancer in Lynch Syndrome: results of long term follow-up in the CAPP2 trial. (program #113). Presented at the 59th Annual Meeting of the American Society of Human Genetics, October 23, 2009, Honolulu, Hawaii. Available at http://www.ashg.org/2009meeting/abstracts/fulltext/.
  18. Casey, G., Lindor, N. M., Papadopoulos, N., Thibodeau, S. N., Moskow, J., Steelman, S., et al. (2005). Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA, 293(7), 799–809.PubMedGoogle Scholar
  19. Catto, J. W. F., Azzouzi, A. R., Amira, N., Rehman, I., Feeley, K. M., Cross, S. S., et al. (2003). Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene, 22, 8699–8706.PubMedGoogle Scholar
  20. Catto, J. W., Azzouzi, A. R., Rehman, I., Feeley, K. M., Cross, S. S., Amira, N., et al. (2005). Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. Journal of Clinical Oncology, 23(13), 2903–2910.PubMedGoogle Scholar
  21. Chao, E. C., Velasquez, J. L., Witherspoon, M. S., Rozek, L. S., Peel, D., Ng, P., et al. (2008). Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Human Mutation, 29(6), 852–860.PubMedGoogle Scholar
  22. Chen, S., Wang, W., Lee, S., Nafa, K., Lee, J., Romans, K., et al. (2006). Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA, 296(12), 1479–1487.PubMedGoogle Scholar
  23. Chen, S., Euhus, D., & Parmigiani, G. (2007). Quantitative models for predicting mutations in Lynch syndrome genes. Current Colorectal Cancer Reports, 3(4), 206–211.Google Scholar
  24. Choi, M. Y., Lauwers, G. Y., Hur, C., Willett, C. G., & Chung, D. C. (2007). Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. International Journal of Radiation Oncology, Biology, Physics, 68(5), 1584.PubMedGoogle Scholar
  25. De Jong, A. E., Morreau, H., Van Puijenbroek, M., Eilers, P. H., Wijnen, J., Nagengast, F. M., et al. (2004a). The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology, 126(1), 42–48.PubMedGoogle Scholar
  26. De Jong, A. E., van Puijenbroek, M., Hendriks, Y., Tops, C., Wijnen, J., Ausems, M. G., et al. (2004b). Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clinical Cancer Research, 10(3), 972–980.PubMedGoogle Scholar
  27. De Jong, A. E., Hendriks, Y. M. C., Kleibeuker, J. H., de Boer, S. Y., Cats, A., Griffioen, G., et al. (2006). Decrease in mortality in lynch syndrome families because of surveillance. Gastroenterology, 130(3), 665–671.PubMedGoogle Scholar
  28. Dijkhuizen, F. P., Mol, B. W., Brolmann, H. A., & Heintz, A. P. (2000). The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer, 89(8), 1765–1772.PubMedGoogle Scholar
  29. Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., et al. (2004). BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. Journal of Medical Genetics, 41(9), 664–668.PubMedGoogle Scholar
  30. Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et al. (2002). The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer, 94(6), 1708–1712.PubMedGoogle Scholar
  31. Dunlop, M. G., Farrington, S. M., Carothers, A. D., Wyllie, A. H., Sharp, L., Burn, J., et al. (1997). Cancer risk associated with germline DNA mismatch repair gene mutations. Human Molecular Genetics, 6(1), 105–110.PubMedGoogle Scholar
  32. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009). Recommendations from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.Google Scholar
  33. Fast Stats (2010). An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. ≤http://seer.cancer.gov/faststats≥. (Accessed on 1-8-2010).
  34. Fenoglio-Preiser, C., Carneiro, F., Correa, P., Guilford, P., Lambert, R., Megraud, F., et al. (2000). Gastric carcinoma. In S. R. Hamilton & L. A. Aaltonen (Eds.), Pathology and genetics of tumours of the digestive system (pp. 39–52). Lyon: IARC.Google Scholar
  35. Gazzoli, I., Loda, M., Garber, J., Syngal, S., & Kolodner, R. D. (2002). A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Research, 62(14), 3925–3928.PubMedGoogle Scholar
  36. Geisler, J. P., Goodheart, M. J., Sood, A. K., Holmes, R. J., Hatterman-Zogg, M. A., & Buller, R. E. (2003). Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer, 98(10), 2199–2206.PubMedGoogle Scholar
  37. Giardiello, F. M., Brensinger, J. D., & Petersen, G. M. (2001). AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology, 121(1), 198–213.PubMedGoogle Scholar
  38. Goodfellow, P. J., Buttin, B. M., Herzog, T. J., Rader, J. S., Gibb, R. K., Swisher, E., et al. (2003). Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America, 100(10), 5908–5913.PubMedGoogle Scholar
  39. Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., et al. (1995). The molecular basis of Turcot’s syndrome. The New England Journal of Medicine, 332(13), 839–847.PubMedGoogle Scholar
  40. Hampel, H. (2009). Genetic testing for hereditary colon cancer. Surgical Oncology Clinics of North America, 18, 687–703.PubMedGoogle Scholar
  41. Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860.PubMedGoogle Scholar
  42. Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J. P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology, 129(2), 415–421.PubMedGoogle Scholar
  43. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810–7817.PubMedGoogle Scholar
  44. Hampel, H., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., Comeras, I., et al. (2007). Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 67(19), 9603.PubMedGoogle Scholar
  45. Hartmann, A., Zanardo, L., Bocker-Edmonston, T., Blaszyk, H., Dietmaier, W., Stoehr, R., et al. (2002). Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Research, 62, 6796–6802.PubMedGoogle Scholar
  46. Hayden, J. D., Martin, I. G., Cawkwell, L., & Quirke, P. (1998). The role of microsatellite instability in gastric carcinoma. Gut, 42, 300–303.PubMedGoogle Scholar
  47. Heinimann, K., Scott, R. J., Buerstedde, J. M., Weber, W., Siebold, K., Attenhofer, M., et al. (1999). Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer. Cancer, 85(12), 2512–2518.PubMedGoogle Scholar
  48. Hendriks, Y. M., Wagner, A., Morreau, H., Menko, F., Stormorken, A., Quehenberger, F., et al. (2004). Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology, 127(1), 17–25.PubMedGoogle Scholar
  49. Hitchins, M. P., & Ward, R. L. (2009). Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. Journal of Medical Genetics, 46(12), 793–802.PubMedGoogle Scholar
  50. Hitchins, M. P., Wong, J. J., Suthers, G., Suter, C. M., Martin, D. I., Hawkins, N. J., et al. (2007). Inheritance of a cancer-associated MLH1 germ-line epimutation. The New England Journal of Medicine, 356(7), 697–705.PubMedGoogle Scholar
  51. Horner, M. J., Ries, L. A. G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., et al. (Eds.). (2009). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site.
  52. Iino, H., Simms, L., Young, J., Arnold, J., Winship, I. M., Webb, S. I., et al. (2000). DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut, 47(1), 37–42.PubMedGoogle Scholar
  53. Jarvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., Peltomaki, P., et al. (2000). Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology, 118(5), 829–834.PubMedGoogle Scholar
  54. Jass, J. R. (2006). Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World Journal of Gastroenterology, 12(31), 4943–4950.PubMedGoogle Scholar
  55. Jass, J. R., & Stewart, S. M. (1992). Evolution of hereditary non-polyposis colorectal cancer. Gut, 33(6), 783–786.PubMedGoogle Scholar
  56. Jenkins, M. A., Hayashi, S., O’Shea, A. M., Burgart, L. J., Smyrk, T. C., Shimizu, D., et al. (2007). Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology, 133(1), 48–56.PubMedGoogle Scholar
  57. Jones, S., Chen, W. D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences, 105(11), 4283–4288.Google Scholar
  58. Kadiyska, T. K., Konstantinova, D. V., Atanasov, V. R., Kremensky, I. M., & Mitev, V. I. (2007). Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for hereditary nonpolyposis colorectal cancer. Cancer Detection and Prevention, 31(3), 254–256.PubMedGoogle Scholar
  59. Kastrinos, F., Mukherjee, B., Tayob, N., Wang, F., Sparr, J., Raymond, V. M., et al. (2009). Risk of pancreatic cancer in families with Lynch syndrome. JAMA, 302(16), 1790–1795.PubMedGoogle Scholar
  60. Kawaguchi, M., Yanokura, M., Banno, K., Kobayashi, Y., Kuwabara, Y., Kobayashi, M., et al. (2009). Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. International Journal of Oncology, 34(6), 1541–1547.PubMedGoogle Scholar
  61. Kim, H. S., Lee, B. L., Woo, D. K., Bae, S. I., & Kim, W. H. (2001). Assessment of markers for the identification of microsatellite instability phenotype in gastric neoplasms. Cancer Letters, 164, 61–68.PubMedGoogle Scholar
  62. Koornstra, J. J., Mourits, M. J. E., Sijmons, R. H., Leliveld, A. M., Hollema, H., & Kleibeuker, J. H. (2009). Management of extracolonic tumours in patients with Lynch syndrome. The Lancet Oncology, 10(4), 400–408.PubMedGoogle Scholar
  63. Kovacs, M. E., Papp, J., Szentirmay, Z., Otto, S., & Olah, E. (2009). Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Human Mutation, 30(2), 197–203.PubMedGoogle Scholar
  64. Kuismanen, S. A., Moisio, A. L., Schweizer, P., Truninger, K., Salovaara, R., Arola, J., et al. (2002). Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. The American Journal of Pathology, 160(6), 1953–1958.PubMedGoogle Scholar
  65. Ligtenberg, M. J. L., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nature Genetics, 41(1), 112–117.PubMedGoogle Scholar
  66. Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., Sargent, D. J., et al. (2002). Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of Clinical Oncology, 20(4), 1043–1048.PubMedGoogle Scholar
  67. Lindor, N. M., Rabe, K., Petersen, G. M., Haile, R., Casey, G., Baron, J., et al. (2005). Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA, 293(16), 1979–1985.PubMedGoogle Scholar
  68. Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA, 296(12), 1507–1517.PubMedGoogle Scholar
  69. Liu, S. R., Zhao, B., Wang, Z. J., Wan, Y. L., & Huang, Y. T. (2004). Clinical features and mismatch repair gene mutation screening in Chinese patients with hereditary nonpolyposis colorectal carcinoma. World Journal of Gastroenterology, 10(18), 2647–2651.PubMedGoogle Scholar
  70. Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., et al. (2007). Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer, 6(3), 301–310.PubMedGoogle Scholar
  71. Loukola, A., Salovaara, R., Kristo, P., Moisio, A. L., Kaariainen, H., Ahtola, H., et al. (1999). Microsatellite instability in adenomas as a marker for hereditary nonpolyposis colorectal cancer. The American Journal of Pathology, 155(6), 1849–1853.PubMedGoogle Scholar
  72. Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158–5164.PubMedGoogle Scholar
  73. Lynch, H. T., & Smyrk, T. (1996). Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer, 78(6), 1149–1167.PubMedGoogle Scholar
  74. Lynch, H. T., Harris, R. E., Lynch, P. M., Guirgis, H. A., Lynch, J. F., & Bardawil, W. A. (1977). Role of heredity in multiple primary cancer. Cancer, 40(4 Suppl), 1849–1854.PubMedGoogle Scholar
  75. Lynch, H. T., Coronel, S. M., Okimoto, R., Hampel, H., Sweet, K., Lynch, J. F., et al. (2004). A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA, 291(6), 718–724.PubMedGoogle Scholar
  76. Maeda, T., Cannom, R. R., Beart, R. W., Jr., & Etzioni, D. A. (2010). Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 28(7), 1175–1180.PubMedGoogle Scholar
  77. Mecklin, J. P., & Jarvinen, H. J. (1986). Clinical features of colorectal carcinoma in cancer family syndrome. Diseases of the Colon and Rectum, 29(3), 160–164.PubMedGoogle Scholar
  78. Miyakura, Y., Sugano, K., Akasu, T., Yoshida, T., Maekawa, M., Saitoh, S., et al. (2004). Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clinical Gastroenterology and Hepatology, 2(2), 147–156.PubMedGoogle Scholar
  79. Muller, W., Burgart, L. J., Krause-Paulus, R., Thibodeau, S. N., Almeida, M., Edmonston, T. B., et al. (2001). The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)–results of an international collaborative study. Fam Cancer, 1(2), 87–92.PubMedGoogle Scholar
  80. Muller, A., Giuffre, G., Edmonston, T. B., Mathiak, M., Roggendorf, B., Heinmoller, E., et al. (2004). Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. The Journal of Molecular Diagnostics, 6(4), 308–315.PubMedGoogle Scholar
  81. Muller, A., Beckmann, C., Westphal, G., Bocker Edmonston, T., Friedrichs, N., Dietmaier, W., et al. (2006). Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. International Journal of Colorectal Disease, 21(7), 632–641.PubMedGoogle Scholar
  82. Myrhøj, T., Andersen, M. B., & Bernstein, I. (2008). Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial Cancer, 7(4), 303–307.PubMedGoogle Scholar
  83. Nakagawa, H., Lockman, J. C., Frankel, W. L., Hampel, H., Steenblock, K., Burgart, L. J., et al. (2004). Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Research, 64(14), 4721–4727.PubMedGoogle Scholar
  84. Niessen, R. C., Kleibeuker, J. H., Westers, H., Jager, P. O., Rozeveld, D., Bos, K. K., et al. (2009). PMS2 involvement in patients suspected of Lynch syndrome. Genes, Chromosomes & Cancer, 48(4), 322–329.Google Scholar
  85. Nystrom-Lahti, M., Wu, Y., Moisio, A. L., Hofstra, R. M., Osinga, J., Mecklin, J. P., et al. (1996). DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Human Molecular Genetics, 5(6), 763–769.PubMedGoogle Scholar
  86. Offit, K. (2004). MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie. Journal of Clinical Oncology, 22(22), 4449–4451.PubMedGoogle Scholar
  87. Ollila, S., Fitzpatrick, R., Sarantaus, L., Kariola, R., Ambus, I., Velsher, L., et al. (2006). The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. International Journal of Oncology, 28(1), 149–153.PubMedGoogle Scholar
  88. Orta, L., Klimstra, D. S., Qin, J., Mecca, P., Tang, L. H., Busam, K. J., et al. (2009). Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient’s age or other clinical characteristics. The American Journal of Surgical Pathology, 33(6), 934–944.PubMedGoogle Scholar
  89. Pal, T., Permuth-Way, J., Kumar, A., & Sellers, T. A. (2008). Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clinical Cancer Research, 14(21), 6847–6854.PubMedGoogle Scholar
  90. Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.PubMedGoogle Scholar
  91. Park, Y. J., Shin, K. H., & Park, J. G. (2000). Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clinical Cancer Research, 6(8), 2994–2998.PubMedGoogle Scholar
  92. Peltomaki, P., & Vasen, H. (2004). Mutations associated with HNPCC predisposition—Update of ICG-HNPCC/INSiGHT mutation database. Disease Markers, 20(4–5), 269–276.PubMedGoogle Scholar
  93. Plaschke, J., Engel, C., Kruger, S., Holinski-Feder, E., Pagenstecher, C., Mangold, E., et al. (2004). Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. Journal of Clinical Oncology, 22(22), 4486–4494.PubMedGoogle Scholar
  94. Ponti, G., Losi, L., Pedroni, M., Lucci-Cordisco, E., Di Gregorio, C., Pellacani, G., et al. (2006). Value of MLH1 and MSH2 Mutations in the Appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. Journal of Investigative Dermatology, 126(10), 2302–2307.PubMedGoogle Scholar
  95. Popat, S., Hubner, R., & Houlston, R. S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology, 23(3), 609–618.PubMedGoogle Scholar
  96. Rahner, N., Hoefler, G., Hogenauer, C., Lackner, C., Steinke, V., Sengteller, M., et al. (2008). Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. American Journal of Medical Genetics. Part A, 146A(10), 1314–1319.PubMedGoogle Scholar
  97. Renkonen-Sinisalo, L., Sipponen, P., Aarnio, M., Julkunen, R., Aaltonen, L. A., Sarna, S., et al. (2002). No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 37(5), 574–577.PubMedGoogle Scholar
  98. Renkonen-Sinisalo, L., Butzow, R., Leminen, A., Lehtovirta, P., Mecklin, J. P., & Jarvinen, H. J. (2007). Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International Journal of Cancer, 120(4), 821–824.Google Scholar
  99. Rijcken, F. E., Hollema, H., & Kleibeuker, J. H. (2002). Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut, 50(3), 382–386.PubMedGoogle Scholar
  100. Rijcken, F. E., Mourits, M. J., Kleibeuker, J. H., Hollema, H., & van der Zee, A. G. (2003). Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology, 91(1), 74–80.PubMedGoogle Scholar
  101. Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Jass, J. R., Khan, P. M., et al. (1997). A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. Journal of the National Cancer Institute, 89(23), 1758–1762.PubMedGoogle Scholar
  102. Roupret, M., Catto, J., Coulet, F., Azzouzi, A. R., Amira, N., Karmouni, T., et al. (2004). Micorsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. Journal of Medical Genetics, 41, e91.PubMedGoogle Scholar
  103. Ruszkiewicz, A., Bennett, G., Moore, J., Manavis, J., Rudzki, B., Shen, L., et al. (2002). Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology, 34(6), 541–547.PubMedGoogle Scholar
  104. Sankila, R., Aaltonen, L. A., Jarvinen, H. J., & Mecklin, J. P. (1996). Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology, 110(3), 682–687.PubMedGoogle Scholar
  105. Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261–269.PubMedGoogle Scholar
  106. Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419–428.PubMedGoogle Scholar
  107. Simpson, A. J. G., Caballero, O. L., & Pena, S. D. J. (2001). Microsatellite instability as a tool for the classification of gastric cancer. Trends in Molecular Medicine, 7(2), 76–80.PubMedGoogle Scholar
  108. Singer, G., Kallinowski, T., Hartmann, A., Dietmaier, W., Wild, P. J., Schraml, P., et al. (2004). Different types of microsatellite instability in ovarian carcinoma. International Journal of Cancer, 112(4), 643–646.Google Scholar
  109. Singh, R. S., Grayson, W., Redston, M., Diwan, A. H., Warneke, C. L., McKee, P. H., et al. (2008). Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. The American Journal of Surgical Pathology, 32(6), 936–942.PubMedGoogle Scholar
  110. South, C. D., Hampel, H., Comeras, I., Westman, J. A., Frankel, W. L., & de la Chapelle, A. (2008). The frequency of Muir-Torre syndrome among Lynch syndrome families. Journal of the National Cancer Institute, 100(4), 277–281.PubMedGoogle Scholar
  111. South, C. D., Yearsley, M., Martin, E., Arnold, M., Frankel, W., & Hampel, H. (2009). Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genetics in Medicine, 11(11), 812–817.PubMedGoogle Scholar
  112. Stoffel, E. M., & Syngal, S. (2005). Adenomas in young patients: what is the optimal evaluation? The American Journal of Gastroenterology, 100(5), 1150–1153.PubMedGoogle Scholar
  113. Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with lynch syndrome. Gastroenterology, 137(5), 1621–1627.PubMedGoogle Scholar
  114. Suter, C. M., Martin, D. I., & Ward, R. L. (2004). Germline epimutation of MLH1 in individuals with multiple cancers. Nature Genetics, 36(5), 497–501.PubMedGoogle Scholar
  115. Syngal, S., Fox, E. A., Eng, C., Kolodner, R. D., & Garber, J. E. (2000). Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. Journal of Medical Genetics, 37(9), 641–645.PubMedGoogle Scholar
  116. Tan, T. Y., Orme, L. M., Lynch, E., Croxford, M. A., Dow, C., Dewan, P. A., et al. (2008). Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. Journal of Pediatric Hematology/Oncology, 30(3), 254–257.PubMedGoogle Scholar
  117. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987a). Combination oral contraceptive use and the risk of endometrial cancer. JAMA, 257(6), 796–800.Google Scholar
  118. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987b). The reduction in risk of ovarian cancer associated with oral-contraceptive use. The New England Journal of Medicine, 316(11), 650–655.Google Scholar
  119. The NCCN Clinical Practice Guidelines in Oncology™ Colorectal Cancer Screening (Version I. 2010). © 2009 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed January 19, 2010. To view the most recent and complete version of the NCCN Guidelines, go online to http://www.nccn.org.
  120. Truninger, K., Menigatti, M., Luz, J., Russell, A., Haider, R., Gebbers, J.-O., et al. (2005). Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology, 128(5), 1160–1171.PubMedGoogle Scholar
  121. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.PubMedGoogle Scholar
  122. van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., et al. (2010). Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of Medical Genetics, 47(7), 464–470.PubMedGoogle Scholar
  123. Vasen, H. F., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Diseases of the Colon and Rectum, 34(5), 424–425.PubMedGoogle Scholar
  124. Vasen, H. F., Watson, P., Mecklin, J. P., Jass, J. R., Green, J. S., Nomizu, T., et al. (1994). The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Research, 14(4B), 1675–1678.PubMedGoogle Scholar
  125. Vasen, H. F., Nagengast, F. M., & Khan, P. M. (1995). Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet, 345(8958), 1183–1184.PubMedGoogle Scholar
  126. Vasen, H. F., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.PubMedGoogle Scholar
  127. Vasen, H. F., Moslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., et al. (2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetics, 44(6), 353–362.PubMedGoogle Scholar
  128. Velayos, F. S., Allen, B. A., Conrad, P. G., Gum, J., Jr., Kakar, S., Chung, D. C., et al. (2005). Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. The American Journal of Gastroenterology, 100(5), 1143–1149.PubMedGoogle Scholar
  129. Wagner, A., Barrows, A., Wijnen, J. T., van der Klift, H., Franken, P. F., Verkuijlen, P., et al. (2003). Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. American Journal of Human Genetics, 72(5), 1088–1100.PubMedGoogle Scholar
  130. Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., et al. (2003). BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Research, 63(17), 5209–5212.PubMedGoogle Scholar
  131. Watson, P., Vasen, H. F., Mecklin, J. P., Bernstein, I., Aarnio, M., Jarvinen, H. J., et al. (2008). The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. International Journal of Cancer, 123(2), 444–449.Google Scholar
  132. Whelan, A. J., Babb, S., Mutch, D. G., Rader, J., Herzog, T. J., Todd, C., et al. (2002). MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. International Journal of Cancer, 99(5), 697–704.Google Scholar
  133. Wijnen, J., van der Klift, H., Vasen, H., Khan, P. M., Menko, F., Tops, C., et al. (1998a). MSH2 genomic deletions are a frequent cause of HNPCC. Nature Genetics, 20(4), 326–328.PubMedGoogle Scholar
  134. Wijnen, J. T., Vasen, H. F., Khan, P. M., Zwinderman, A. H., van der Klift, H., Mulder, A., et al. (1998b). Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. The New England Journal of Medicine, 339(8), 511–518.PubMedGoogle Scholar
  135. Wijnen, J., de Leeuw, W., Vasen, H., van der Klift, H., Moller, P., Stormorken, A., et al. (1999). Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics, 23(2), 142–144.PubMedGoogle Scholar
  136. Winawer, S. J., Zauber, A. G., Ho, M. N., O’Brien, M. J., Gottlieb, L. S., Sternberg, S. S., et al. (1993). Prevention of colorectal cancer by colonoscopic polypectomy. NEJM, 329(27), 1977–1981.PubMedGoogle Scholar
  137. Zighelboim, I., Powell, M., Babb, S., Whelan, A., Schmidt, A., Clendenning, M., et al. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 8(4), 501–504.PubMedGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2010

Authors and Affiliations

  • Scott M. Weissman
    • 1
  • Cecelia Bellcross
    • 2
  • Christina Chimera Bittner
    • 3
  • Mary E. Freivogel
    • 4
    • 5
  • Joy Larsen Haidle
    • 6
  • Pardeep Kaurah
    • 7
  • Anna Leininger
    • 8
  • Selvi Palaniappan
    • 9
  • Kelle Steenblock
    • 5
  • Thuy M. Vu
    • 10
  • Molly S. Daniels
    • 11
  1. 1.Center for Medical GeneticsNorthShore University HealthSystemEvanstonUSA
  2. 2.Hematology/Oncology Clinic, Dean Health SystemMadisonUSA
  3. 3.University of Pittsburgh Medical Center Cancer Genetics Program, Magee-Womens HospitalPittsburghUSA
  4. 4.Risk Assessment and Prevention Program, Invision Sally JobeGreenwood VillageUSA
  5. 5.Informed Medical Decisions, Inc.St. PetersburgUSA
  6. 6.Humphrey Cancer Center, North Memorial HealthcareRobbinsdaleUSA
  7. 7.Hereditary Cancer Program, British Columbia Cancer AgencyVancouverCanada
  8. 8.William C. Berstein Familial Cancer RegistryMinneapolisUSA
  9. 9.Hereditary Cancer ProgramNorthside HospitalAtlantaUSA
  10. 10.Department of Surgical OncologyThe University of Texas M.D. Anderson Cancer CancerHoustonUSA
  11. 11.Department of Gynecologic OncologyThe University of Texas M.D. Anderson Cancer CancerHoustonUSA

Personalised recommendations